Eculizumab (Soliris®) for the treatment of patients with paroxysmal nocturnal haemogloninuria

The National Health Care Institute has re-assessed the medicine eculizumab (Soliris®) for the treatment of patients with paroxysmal nocturnal haemogloninuria (PNH). The National Health Care Institute reached the following conclusion. Based on necessity, effectiveness, cost-effectiveness and feasibility (the package criteria), eculizumab should no longer be reimbursed from the basic health insurance, unless there is clear insight into its cost-effectiveness (and in a case of unfavourable cost-effectiveness) transparency regarding how the price was determined.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.